Research programme: bacterial biofilm inhibitors - ProclaRx

Drug Profile

Research programme: bacterial biofilm inhibitors - ProclaRx

Alternative Names: PCL 1402; PCL 1440; PCL 1550; PCL-1404; PCL-1406; PCL-1407

Latest Information Update: 29 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nationwide Children's Hospital; Ohio State University; University of Southern California
  • Developer ProclaRx
  • Class Antibodies; Vaccines
  • Mechanism of Action Bacterial outer membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Infections; Otitis media; Sinusitis

Most Recent Events

  • 18 Jun 2018 ProclaRx plans phase I trial for Otitis media in 2018 (ProclaRx pipeline, June 2018)
  • 18 Jun 2018 ProclaRx plans phase I trial for Sinusitis in 2019 (ProclaRx pipeline, June 2018)
  • 18 Jun 2018 ProclaRx plans phase II/III trial for Otitis media in 2019 (ProclaRx pipeline, June 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top